Form 8-K - Current report:
SEC Accession No. 0000950170-22-024193
Filing Date
2022-11-10
Accepted
2022-11-10 08:30:17
Documents
16
Period of Report
2022-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20221110.htm   iXBRL 8-K 65416
2 EX-99.1 cadl-ex99_1.htm EX-99.1 71215
3 GRAPHIC img160460863_0.jpg GRAPHIC 26587
4 GRAPHIC img160460863_1.jpg GRAPHIC 73198
5 GRAPHIC img160460863_2.jpg GRAPHIC 35706
  Complete submission text file 0000950170-22-024193.txt   449403

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20221110_pre.xml EX-101.PRE 11387
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20221110_lab.xml EX-101.LAB 14711
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20221110.xsd EX-101.SCH 2464
10 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20221110_htm.xml XML 4884
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 221375112
SIC: 2836 Biological Products, (No Diagnostic Substances)